Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | CLL treatment: novel agents vs. cellular therapies

Matthew Davids • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia CAR-T

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the debate held between academics as to the efficacy and toxicities of cellular therapies compared to novel agents and the roles both are to play in the future of chronic lymphocytic leukemia (CLL) treatment. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Matthew Davids

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
1:53
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids • 9 Dec 2023
2:15
CDK9 inhibition with voruciclib for treating AML and R/R B-cell NHL
Matthew Davids • 9 Dec 2023
1:21
Clinical characteristics and outcomes of the double refractory CLL/SLL patient population
Matthew Davids • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals